

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO. CONFIRMATION NO.	
09/402,614	03/01/2000	GAIL PETUNA RISBRIDGER	229752000800	6186
	90 12/28/2004		EXAMINER	
MORRISON & FOERSTER LLP 1650 TYSONS BLVD			NICKOL, GARY B	
SUITE 300	TE 300 ART UNIT PA		PAPER NUMBER	
MCLEAN, VA	22102		1642	
			DATE MAILED: 12/28/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)
Office Action Summary		09/402,614	RISBRIDGER ET AL.
		Examiner	Art Unit
		Gary B. Nickol Ph.D.	1642
Period fo	The MAILING DATE of this communication ap	pears on the cover sheet with the	correspondence address
A SH THE - Exte after - If the - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPL MAILING DATE OF THIS COMMUNICATION. Insions of time may be available under the provisions of 37 CF1. SIX (6) MONTHS from the mailing date of this communication. It is period for reply specified above is less than thirty (30) days, a reput of the provision of th	136(a). In no event, however, may a reply be ly within the statutory minimum of thirty (30) d will apply and will expire SIX (6) MONTHS froe, cause the application to become ABANDON	timely filed ays will be considered timely. in the mailing date of this communication. NED (35 U.S.C. § 133).
Status			
	Responsive to communication(s) filed on 30 S. This action is FINAL . 2b) This Since this application is in condition for alloward closed in accordance with the practice under the second seco	s action is non-final. Ince except for formal matters, p	
Dispositi	on of Claims		
5)	Claim(s) 1-58,60-63 and 69-99 is/are pending 4a) Of the above claim(s) 1-57,63 and 92 is/are Claim(s) is/are allowed. Claim(s) 58,60-62,69-91 and 93-99 is/are rejected to. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or on Papers The specification is objected to by the Examine The drawing(s) filed on is/are: a) accomplicant may not request that any objection to the Replacement drawing sheet(s) including the correct.	e withdrawn from consideration. cted. or election requirement. er. epted or b) objected to by the drawing(s) be held in abeyance. So tion is required if the drawing(s) is o	ee 37 CFR 1.85(a). bjected to. See 37 CFR 1.121(d).
' ')	The oath or declaration is objected to by the Ex	kaminer. Note the attached Offic	e Action or form PTO-152.
12)[a)[Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureau ee the attached detailed Office action for a list	s have been received. s have been received in Applica rity documents have been receiv u (PCT Rule 17.2(a)).	tion No ved in this National Stage
Attachment		_	
2) 🔲 Notice 3) 🔲 Inforn	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) No(s)/Mail Date	4) Interview Summar Paper No(s)/Mail E 5) Notice of Informal 6) Other:	

Page 2

Art Unit: 1642

Re: Risbridger et al.

Date of priority: 04/23/1997

Response to Amendment

The Amendment filed 09-30-2004 in response to the Office Action of 03-30-2004 is acknowledged and has been entered.

Claims 69-99 were newly added.

Claims 1-57, 63, 92 are withdrawn.

Claims 58, 60-62, 69-91, and 93-99 are currently under consideration.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office Action.

Election/Restriction

The requirement for a species election (Action mailed 09-03-2001) between αN and αC is withdrawn (Claims 61 and 62). Thus, claim 61 is now newly pending.

Newly submitted claims 63 and 92 are directed to an invention that is independent or distinct from the invention originally claimed for the following reasons: Claims 63 and 92 are drawn to

Art Unit: 1642

detecting changes in the expression levels of inhibin, i.e. mRNA which is independent and or distinct from the originally elected invention of detection inhibin protein levels.

Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits.

Accordingly, claims 63 and 92 are withdrawn from consideration as being directed to a non-

elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

Rejections Withdrawn:

The rejection of Claims 58, 60, and 62-63 as being anticipated by Teni *et al.* (Clinical Chemistry, Volume 35, No. 7, pages 1376-1379, 1989) is withdrawn. Applicants have provided evidence (Response, 09-03-04) and the art of record (Risbridger *et al.*, Jnl.Endocrinology, 1996, IDS) indicates that inhibins are structurally and functionally unrelated to prostatic inhibin-like peptide ("PIP"), also known as Beta-microseminoprotein.

All other rejections and or objections are withdrawn in view of applicant's amendments and arguments there to.

Rejections Maintained:

Claims 58, 60, 62, remain rejected and new claims 61*, 69-91, 93-99 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a method of

Art Unit: 1642

screening for a mammal having prostate cancer comprising determining the amount of inhibin protein levels in both cancerous and corresponding normal prostate samples, wherein the presence of prostate cancer is verified by the *absence* of inhibin protein in the cancerous samples versus the normal samples, does not reasonably provide enablement for the broadly claimed invention for the reasons of record. Applicant's claims remain drawn to screening for those who are "predisposed" to develop prostate cancer. In their response, applicants did not address this limitation. As set forth previously, neither the specification nor any art of record indicates, suggests, or teaches that down-regulation or the absence of inhibin would lead one of ordinary skill in the art to predictably determine a predisposition to prostate cancer in an otherwise normal healthy mammal. Furthermore, newly independent claims 83 and 95 do not include the essential step of of comparing inhibin levels such that the down-regulation and or absence of inhibin protein in the cancerous samples is observed. Thus, the rejection is maintained for the reasons of record.

*Previously withdrawn

New Objections/Rejections:

Claims 76 and 86 are rejected for reciting, "dimmer" as this appears to be a spelling error.

Claim 83 is objected to for reciting, "with a level know" which appears to be a grammatical

error.

Claim 86 is objected to for reciting, "wherein level" which appears to be a grammatical error.

Application/Control Number: 09/402,614

Art Unit: 1642

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 70-71 recite "the change" or "said change". There is insufficient antecedent basis for this limitation from which claims 70-71 depend.

Claim 73 recites "said screening <u>process</u>". There is insufficient antecedent basis for this limitation from which claim 73 depends.

No claim is allowed.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event,

Art Unit: 1642

however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gary B. Nickol Ph.D. whose telephone number is 571-272-0835. The examiner can normally be reached on M-Th, 8:30-5:30; alternate Fri., 8:30-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Gary B. Nickol Ph.D. Primary Examiner Art Unit 1642

ary Brukal

GBN

GARY NĬCKOL PRIMARY EXAMINER